This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juno Therapeutics Inc.
Drug Names(s): Engineered Neuroblastoma Cellular Immunotherapy-01, Chimeric Antigen Receptor T Cells, CD171 CAR T, L1CAM, ENCIT-01
Description: ENCIT-01 (Engineered Neuroblastoma Cellular Immunotherapy) is a chimeric antigen receptor (CAR) T cell product comprised of autologous T cells. After aphresis, the patient's T cells are lentivirally transduced to express a CD171 CAR and a truncated EGFR receptor.
Additional information available to subscribers only: